Table 2.
Subgroup analysis of mortality with cefazolin versus ASPs for the treatment of MSSA bacteremia
| Variable | No. of studies | No. of patients | OR (95% CI) | P Value | I2% |
|---|---|---|---|---|---|
| Study design | |||||
| Retrospective | 8 | 4212 | 0.71 (0.59–0.84) | 0.57 | 0 |
| Prospective | 2 | 258 | 0.27 (0.09–0.79) | 0.46 | 0 |
| Location | |||||
| USA | 5 | 3670 | 0.71 (0.59–0.86) | 0.52 | 0 |
| Other | 5 | 800 | 0.57 (0.36–0.91) | 0.25 | 25.4 |
| Study period | |||||
| Initiated before 2008 | 4 | 3782 | 0.58 (0.36–0.92) | 0.15 | 43.4 |
| Initiated after 2008 | 6 | 688 | 0.71 (0.59–0.85) | 0.64 | 0 |
| Mortality recording time | |||||
| 30-day mortality | 6 | 3676 | 0.60 (0.48–0.75) | 0.81 | 0 |
| 90-day mortality | 7 | 4133 | 0.69 (0.58–0.82) | 0.30 | 16.9 |
| Adjustment | |||||
| Propensity score matched or multiple adjusted | 6 | 4040 | 0.69 (0.58–0.83) | 0.26 | 23.6 |
| Unadjusted | 10 | 4779 | 0.74 (0.64–0.87) | 0.11 | 37.6 |
| Control group | |||||
| NAF or OXA | 7 | 3910 | 0.69 (0.57–0.83) | 0.26 | 22.6 |
| CLX | 3 | 560 | 0.69 (0.42–1.12) | 0.46 | 0 |
ASPs antistaphylococcal penicillins, CFZ cefazolin, CI confidence interval, CLX cloxacillin, MSSA methicillin-susceptible Staphylococcus aureus, NAF nafcillin, OR odds ratio, OXA oxacillin